SEC Form 4 · accession 0001140361-18-015300
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederick W Gluck
Director
Period of report
Mar 26, 2018
Accepted (ET)
Mar 27, 2018 · 8:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Mar 26, 2018 | S | 5,000 | $31.9283 | D | 271,643 | I | By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 |
| Common StockF4 | holding | — | — | — | 22,111 | I | By Richlin Partners, LLC | |
| Common Stock | holding | — | — | — | 3,200 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.70 to $32.18, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997.
- F4Richlin Partners, LLC is an entity owned of record by the spouse of the Reporting Person.